The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity
The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2006-11, Vol.65 (suppl 3), p.iii34-iii36 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | iii36 |
|---|---|
| container_issue | suppl 3 |
| container_start_page | iii34 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 65 |
| creator | Cancro, M P |
| description | The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis. |
| doi_str_mv | 10.1136/ard.2006.058412 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1798379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68964130</sourcerecordid><originalsourceid>FETCH-LOGICAL-b522t-2c965248fb08d9d2f914ee59e555c233def64759f68d16f1626d112fb225133</originalsourceid><addsrcrecordid>eNqFkU2P0zAQhiMEYsvCmRuyhOCAlNYfsWNzQNotlAVVgLSrhZvlJHbXbeIU20Hk3-OSahe4cLA91jzzambeLHuK4BwhwhbKN3MMIZtDyguE72UzVDCeY8jg_WwGISR5IVh5kj0KYZu-kCP-MDtBJSS8YGKW7a5uNDhfj5eL87PVChjV2XYEvQGt3SjXBJAu4HWt97H34TXY6RFE5Tc6BmAdiKk6Ha_2429ycI32IabQus1BRg2xt103OBvHx9kDo9qgnxzf0-xy9e5qeZGvP7__sDxb5xXFOOa4FozigpsK8kY02AhUaE2FppTWmJBGG1aUVBjGG8QMYpg1CGFTYUwRIafZm0l1P1Sdbmrtolet3HvbKT_KXln5d8bZG7npf0hUCk5KkQReHgV8_33QIcrOhlq3rXK6H4JkXLACEZjA5_-A237wLo2WtMqS07TmIlGLiap9H4LX5rYVBOXBRJlMlAcT5WRiqnj25wR3_NG1BLw4AirUqjVeudqGO46n7SFGE5dPnA1R_7zNK7-TrCQllZ-ul_LL6uLj17f0Wn5L_KuJr7rtf7v8Bb6ZwWo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777851704</pqid></control><display><type>article</type><title>The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cancro, M P</creator><creatorcontrib>Cancro, M P</creatorcontrib><description>The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2006.058412</identifier><identifier>PMID: 17038469</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>a proliferation inducing ligand ; Animals ; Antigens ; APRIL ; Autoimmune Diseases - immunology ; Autoimmune Diseases - therapy ; Autoimmunity ; B cell maturation antigen ; B cell receptor ; B lymphocyte stimulator ; B-Cell Activating Factor - immunology ; B-Cell Activation Factor Receptor - immunology ; B-Lymphocytes - immunology ; BCMA ; BCR ; Biological and medical sciences ; BLyS ; BLyS receptor 3 ; Bone marrow ; BR3 ; Cells ; Diseases of the osteoarticular system ; Homeostasis - immunology ; Humans ; Ligands ; Lymphocyte Activation - immunology ; Medical sciences ; receptors ; TACI ; targets ; TNF ; transmembrane activator and calcium modulator and cyclophylin ligand interactor ; Tumor necrosis factor-TNF ; tumour necrosis factor</subject><ispartof>Annals of the rheumatic diseases, 2006-11, Vol.65 (suppl 3), p.iii34-iii36</ispartof><rights>Copyright 2006 by Annals of the Rheumatic Diseases</rights><rights>2007 INIST-CNRS</rights><rights>Copyright: 2006 Copyright 2006 by Annals of the Rheumatic Diseases</rights><rights>Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b522t-2c965248fb08d9d2f914ee59e555c233def64759f68d16f1626d112fb225133</citedby><cites>FETCH-LOGICAL-b522t-2c965248fb08d9d2f914ee59e555c233def64759f68d16f1626d112fb225133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/65/suppl_3/iii34.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/65/suppl_3/iii34.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,230,309,310,314,723,776,780,785,786,881,3183,23550,23909,23910,25118,27901,27902,53766,53768,77343,77374</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18248165$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17038469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cancro, M P</creatorcontrib><title>The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.</description><subject>a proliferation inducing ligand</subject><subject>Animals</subject><subject>Antigens</subject><subject>APRIL</subject><subject>Autoimmune Diseases - immunology</subject><subject>Autoimmune Diseases - therapy</subject><subject>Autoimmunity</subject><subject>B cell maturation antigen</subject><subject>B cell receptor</subject><subject>B lymphocyte stimulator</subject><subject>B-Cell Activating Factor - immunology</subject><subject>B-Cell Activation Factor Receptor - immunology</subject><subject>B-Lymphocytes - immunology</subject><subject>BCMA</subject><subject>BCR</subject><subject>Biological and medical sciences</subject><subject>BLyS</subject><subject>BLyS receptor 3</subject><subject>Bone marrow</subject><subject>BR3</subject><subject>Cells</subject><subject>Diseases of the osteoarticular system</subject><subject>Homeostasis - immunology</subject><subject>Humans</subject><subject>Ligands</subject><subject>Lymphocyte Activation - immunology</subject><subject>Medical sciences</subject><subject>receptors</subject><subject>TACI</subject><subject>targets</subject><subject>TNF</subject><subject>transmembrane activator and calcium modulator and cyclophylin ligand interactor</subject><subject>Tumor necrosis factor-TNF</subject><subject>tumour necrosis factor</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU2P0zAQhiMEYsvCmRuyhOCAlNYfsWNzQNotlAVVgLSrhZvlJHbXbeIU20Hk3-OSahe4cLA91jzzambeLHuK4BwhwhbKN3MMIZtDyguE72UzVDCeY8jg_WwGISR5IVh5kj0KYZu-kCP-MDtBJSS8YGKW7a5uNDhfj5eL87PVChjV2XYEvQGt3SjXBJAu4HWt97H34TXY6RFE5Tc6BmAdiKk6Ha_2429ycI32IabQus1BRg2xt103OBvHx9kDo9qgnxzf0-xy9e5qeZGvP7__sDxb5xXFOOa4FozigpsK8kY02AhUaE2FppTWmJBGG1aUVBjGG8QMYpg1CGFTYUwRIafZm0l1P1Sdbmrtolet3HvbKT_KXln5d8bZG7npf0hUCk5KkQReHgV8_33QIcrOhlq3rXK6H4JkXLACEZjA5_-A237wLo2WtMqS07TmIlGLiap9H4LX5rYVBOXBRJlMlAcT5WRiqnj25wR3_NG1BLw4AirUqjVeudqGO46n7SFGE5dPnA1R_7zNK7-TrCQllZ-ul_LL6uLj17f0Wn5L_KuJr7rtf7v8Bb6ZwWo</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Cancro, M P</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>Elsevier Limited</general><general>BMJ Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20061101</creationdate><title>The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity</title><author>Cancro, M P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b522t-2c965248fb08d9d2f914ee59e555c233def64759f68d16f1626d112fb225133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>a proliferation inducing ligand</topic><topic>Animals</topic><topic>Antigens</topic><topic>APRIL</topic><topic>Autoimmune Diseases - immunology</topic><topic>Autoimmune Diseases - therapy</topic><topic>Autoimmunity</topic><topic>B cell maturation antigen</topic><topic>B cell receptor</topic><topic>B lymphocyte stimulator</topic><topic>B-Cell Activating Factor - immunology</topic><topic>B-Cell Activation Factor Receptor - immunology</topic><topic>B-Lymphocytes - immunology</topic><topic>BCMA</topic><topic>BCR</topic><topic>Biological and medical sciences</topic><topic>BLyS</topic><topic>BLyS receptor 3</topic><topic>Bone marrow</topic><topic>BR3</topic><topic>Cells</topic><topic>Diseases of the osteoarticular system</topic><topic>Homeostasis - immunology</topic><topic>Humans</topic><topic>Ligands</topic><topic>Lymphocyte Activation - immunology</topic><topic>Medical sciences</topic><topic>receptors</topic><topic>TACI</topic><topic>targets</topic><topic>TNF</topic><topic>transmembrane activator and calcium modulator and cyclophylin ligand interactor</topic><topic>Tumor necrosis factor-TNF</topic><topic>tumour necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cancro, M P</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cancro, M P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>65</volume><issue>suppl 3</issue><spage>iii34</spage><epage>iii36</epage><pages>iii34-iii36</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>17038469</pmid><doi>10.1136/ard.2006.058412</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2006-11, Vol.65 (suppl 3), p.iii34-iii36 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1798379 |
| source | MEDLINE; BMJ Journals - NESLi2; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | a proliferation inducing ligand Animals Antigens APRIL Autoimmune Diseases - immunology Autoimmune Diseases - therapy Autoimmunity B cell maturation antigen B cell receptor B lymphocyte stimulator B-Cell Activating Factor - immunology B-Cell Activation Factor Receptor - immunology B-Lymphocytes - immunology BCMA BCR Biological and medical sciences BLyS BLyS receptor 3 Bone marrow BR3 Cells Diseases of the osteoarticular system Homeostasis - immunology Humans Ligands Lymphocyte Activation - immunology Medical sciences receptors TACI targets TNF transmembrane activator and calcium modulator and cyclophylin ligand interactor Tumor necrosis factor-TNF tumour necrosis factor |
| title | The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A01%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20BLyS/BAFF%20family%20of%20ligands%20and%20receptors:%20key%20targets%20in%20the%20therapy%20and%20understanding%20of%20autoimmunity&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Cancro,%20M%20P&rft.date=2006-11-01&rft.volume=65&rft.issue=suppl%203&rft.spage=iii34&rft.epage=iii36&rft.pages=iii34-iii36&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2006.058412&rft_dat=%3Cproquest_pubme%3E68964130%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777851704&rft_id=info:pmid/17038469&rfr_iscdi=true |